Measuring DNA Damage from Antibody Therapy in Cancer
Author Information
Author(s): Webley S D, Francis R J, Pedley R B, Sharma S K, Begent R H J, Hartley J A, Hochhauser D
Primary Institution: Royal Free and University College School of Medicine, University College London
Hypothesis
The study investigates the effectiveness of antibody-directed enzyme prodrug therapy (ADEPT) in producing DNA lesions in cancer cells.
Conclusion
The study found that while most patients showed no DNA damage from the treatment, one patient did show significant DNA crosslinking and a clinical response.
Supporting Evidence
- The prodrug ZD2767P showed a 229-fold increase in activity when combined with the enzyme CPG2.
- DNA interstrand crosslinks were detected within 1 hour of treatment and repaired by 24 hours.
- In a clinical trial, one patient showed significant DNA damage and a clinical response, while four others did not.
Takeaway
This study looked at a new cancer treatment and found that it can cause DNA damage in some patients, which might help fight the cancer.
Methodology
The study used a modified comet assay to measure DNA interstrand crosslinks in vitro and in clinical samples.
Limitations
Only one patient showed a positive response, and four patients did not demonstrate any DNA damage or tumor response.
Participant Demographics
Patients were part of a phase I clinical trial for ADEPT targeting CEA-positive tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website